Studies have shown that simultaneous blockade of both activin A and MSTN, both ligands of ActRIIA/B, produces greater increases in muscle mass than inhibiting either alone.[82] This finding is supported by clinical trials, where combined treatment with trevogrumab (anti-MSTN) and garetosmab (anti-activin A) increased total body muscle volume and reduced fat mass compared with placebo or either antibody alone.[83] Overall, activin A inhibitors are as promising as MSTN inhibitors, and their combination may yield superior outcomes
While probiotics have a generally favorable safety profile, individual reactions vary
Originally developed for metabolic conditions like type 2 diabetes and obesity, GLP-1s have been demonstrated to reduce major cardiovascular events, improve heart failure
Vitamin D deficiency was most common, affecting 13.6% within 12 months
Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs
Find articles by Momen, A
